TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP

AI Briefing

• – Theravance Biopharma's shares collapsed after a pivotal trial failed, missing guidance, and the company failed to disclose the material risk of failure.
• – The company reaffirmed financial guidance without disclosing the uncertainty of the trial outcome.
• – Shareholders lost approximately 26% of their investment in the days following the failed trial.